MeSH term
Frequency | Condition_Probility | Comparative Study | 3 | 0.0 |
Humans | 29 | 0.0 |
Perfusion | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Stress, Mechanical | 2 | 0.0 |
Time Factors | 3 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Cyclooxygenase Inhibitors/pharmacology | 2 | 2.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 3 | 4.0 |
Research Support, Non-U.S. Gov't | 15 | 0.0 |
Adult | 4 | 0.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Glycosaminoglycans/analysis | 2 | 20.0 |
Middle Aged | 6 | 0.0 |
Animals | 17 | 0.0 |
Prostaglandin-Endoperoxide Synthase/*physiology | 2 | 18.0 |
Cattle | 3 | 0.0 |
Dinoprostone/*biosynthesis | 2 | 4.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis/genetics | 3 | 21.0 |
Base Sequence | 3 | 0.0 |
Female | 10 | 0.0 |
Gene Expression | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Pregnancy | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 10 | 0.0 |
DNA Primers | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Forskolin/pharmacology | 2 | 0.0 |
Indomethacin/*pharmacology | 2 | 5.0 |
Kinetics | 4 | 0.0 |
Male | 7 | 0.0 |
Models, Biological | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Rats | 7 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Mice | 3 | 0.0 |
Prostaglandins/*biosynthesis | 3 | 6.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Aged | 3 | 0.0 |
Biotransformation | 2 | 0.0 |
Prostaglandin-Endoperoxide Synthase/genetics/metabolism | 2 | 28.0 |
Prostaglandins/*pharmacology | 2 | 8.0 |
Indomethacin/pharmacology | 5 | 2.0 |
Arachidonic Acid | 2 | 3.0 |
Dogs | 3 | 0.0 |
Dinoprost | 3 | 8.0 |
Dinoprostone | 2 | 2.0 |
Prostaglandins/*physiology | 2 | 8.0 |
Protein Binding | 2 | 0.0 |
Prostaglandins F/*blood | 2 | 13.0 |
Alprostadil | 2 | 15.0 |
